CMMI director Adam Boehler appointed to advise on value-based care innovations

Adam Boehler, the director of the Center for Medicare & Medicaid Innovation (CMMI), has been appointed to serve as a senior adviser to HHS’s Value-Based Transformation and Innovation.

The value-based care initiative is one of four key department priorities identified by HHS Secretary Alex Azar. Boehler was appointed to CMMI earlier this year. He previously served as CEO of healthcare startup Landmark Health, which he founded in 2013 and provides in-home care to chronically ill patients.

“Adam is the kind of results-oriented, transformational leader we need to deliver on what President Trump has promised the American people: better healthcare at a lower cost,” Azar said in a statement. “At CMMI, he has already demonstrated an ambition for bold change, and will now be able to bring his deep experience with private sector innovation to help HHS execute on the long-talked-about goal of transforming our healthcare system into one that pays for value.”

The agency has appointed three other senior advisors to lead the priorities. Jim Parker was named senior advisor for Health Reform and director of the Office of Health Reform, Dan Best was appointed senior advisor for Drug Pricing Reform and Brett Giroir, MD, was named senior advisor for Opioid and Mental Health Policy.

The four advisors will aim to advance the four initiatives of the agency.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.